预约演示
更新于：2025-04-17
Ruxolitinib Phosphate
磷酸芦可替尼
更新于：2025-04-17
概要
基本信息
药物类型 小分子化药 |
别名 Jakabi、RUX、ruxolitinib (as phosphate) + [12] |
作用方式 抑制剂 |
作用机制 JAK1抑制剂(酪氨酸蛋白激酶JAK1抑制剂)、JAK2抑制剂(酪氨酸蛋白激酶JAK2抑制剂) |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2011-11-16), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (澳大利亚)、优先审评 (澳大利亚)、加速审评 (欧盟)、孤儿药 (日本) |
登录后查看时间轴
结构/序列
分子式C17H21N6O4P |
InChIKeyJFMWPOCYMYGEDM-XFULWGLBSA-N |
CAS号1092939-17-7 |
关联
446
项与 磷酸芦可替尼 相关的临床试验NCT06824103
A Single-arm Multi-center Study of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft Versus Host Disease After Allogeneic Stem Cell Transplantation
NCT06804811
A Phase 3, Randomized, Double-Blind, Efficacy, and Safety Study of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
NCT06859424
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients with Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
100 项与 磷酸芦可替尼 相关的临床结果
登录后查看更多信息
100 项与 磷酸芦可替尼 相关的转化医学
登录后查看更多信息
100 项与 磷酸芦可替尼 相关的专利（医药）
登录后查看更多信息
3,408
项与 磷酸芦可替尼 相关的文献（医药）2025-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Ruxolitinib cream monotherapy for facial and/or neck atopic dermatitis: results from a decentralized, randomized phase 2 clinical trial
Article
作者: Lai, Zhihong ; Cotliar, Jonathan ; Kuo, YuTzu ; Chiesa Fuxench, Zelma C. ; Nawaz, Haq
PURPOSE:
Ruxolitinib cream was evaluated in patients with facial/neck atopic dermatitis (AD) in a decentralized, double-blind, randomized clinical trial (NCT05127421).
MATERIALS AND METHODS:
Patients aged 12-70 years with AD (Investigator's Global Assessment [IGA] score 2/3, ≤20% affected body surface area [face/neck, ≥0.5%]) were randomized 2:1 to twice-daily 1.5% ruxolitinib cream or vehicle for 4 weeks; thereafter, all patients applied as-needed ruxolitinib cream for 4 additional weeks. The primary endpoint was ≥75% improvement in head/neck Eczema Area and Severity Index (EASI-75) at Week 4 assessed by blinded central reader using photographs.
RESULTS:
Among 77 randomized patients (median [range] age, 38.0 [17-66] y), 44.2% were Black. The mean (SD) baseline head/neck EASI was 1.2 (0.7). More patients who applied ruxolitinib cream vs vehicle achieved head/neck EASI-75 at Week 4 (37.0% vs 17.4%; p = 0.091). Improvements with ruxolitinib cream vs vehicle were observed for facial/neck IGA treatment success (IGA 0/1 with ≥2-point improvement from baseline) and Patient-Oriented Eczema Measure (overall and itch). Ruxolitinib cream was well tolerated, including on the face and neck. Application site reactions were infrequent (ruxolitinib cream, 1.9% [n = 1]; vehicle, 8.7% [n = 2]).
CONCLUSIONS:
Ruxolitinib cream improved signs and symptoms of facial/neck AD vs vehicle and was well tolerated.
2025-12-01Blood Research
Reversibility of acrocyanosis and improvement of capillaroscopic pattern in a patient with polycythemia vera treated with ruxolitinib: a case report
Article
作者: Nigro, Angelo
Abstract:
This case report describes the clinical course of a 78-year-old patient diagnosed with polycythemia vera (PV), who presented with pronounced acrocyanosis of the hands in 2021. The patient was treated with hydroxyurea (oncocarbide), and nailfold capillaroscopy revealed an “abnormal pattern” characterized by pronounced architectural disarray and capillary tortuosity, which is uncommon in patients with myeloproliferative neoplasms (MPNs). In 2023, owing to suboptimal symptom management and hematological side effects, the treatment was switched to ruxolitinib, which led to significant clinical improvements by 2024, including near-complete resolution of acrocyanosis and substantial improvement in capillaroscopic abnormalities, with only residual capillary tortuosity noted. This case emphasizes the need for individualized therapeutic interventions for PV, and underscores the potential role of ruxolitinib in ameliorating microvascular dysfunction.
2025-06-01Molecular Therapy-Nucleic Acids
Inhibition of IFNAR-JAK signaling enhances tolerability and transgene expression of systemic non-viral DNA delivery
Article
作者: Wicks, Joan ; Markusic, David M ; Cejas, Pedro J ; Senapati, Sujata ; Herzog, Roland W ; Bertolini, Thais B ; Walsh, Matthew C ; Nahvi, Ali ; Yazicioglu, Mustafa N ; Minnier, Michael A ; Armour, Sean M ; Zhang, Rui
Lipid nanoparticles (LNPs) have demonstrated significant therapeutic value for non-viral delivery of mRNA and siRNA. While there is considerable interest in utilizing LNPs for delivering DNA (DNA-LNPs) to address a broad range of genetic disorders, acute inflammatory responses pose significant safety concerns and limit transgene expression below therapeutically relevant levels. However, the mechanisms and immune signaling pathways underlying DNA-LNP-triggered inflammatory responses are not well characterized. Through the use of gene-targeted mouse models, we have identified cGAS-STING and interferon-α/β receptor (IFNAR) pathways as major mediators of acute inflammation triggered by systemic delivery of DNA-LNPs. cGAS-STING activation induces expression of numerous JAK-STAT-activating cytokines, and we show that treatment of mice with the JAK inhibitors ruxolitinib or baricitinib significantly improves tolerability to systemically delivered DNA-LNPs. Furthermore, specific inhibition of IFNAR signaling enhances both DNA-LNP tolerability and transgene expression. Utilization of JAK inhibitors or IFNAR blockade represent promising strategies for enhancing the safety and efficacy of non-viral DNA delivery for gene therapy.
100 项与 磷酸芦可替尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 非节段型白癜风 | 美国 | 2022-07-18 | |
| 特应性皮炎 | 美国 | 2021-09-21 | |
| 原发性血小板增多症 | 中国 | 2017-03-10 | |
| 急性移植物抗宿主病 | 欧盟 | 2012-08-23 | |
| 急性移植物抗宿主病 | 冰岛 | 2012-08-23 | |
| 急性移植物抗宿主病 | 列支敦士登 | 2012-08-23 | |
| 急性移植物抗宿主病 | 挪威 | 2012-08-23 | |
| 慢性移植物抗宿主病 | 欧盟 | 2012-08-23 | |
| 慢性移植物抗宿主病 | 冰岛 | 2012-08-23 | |
| 慢性移植物抗宿主病 | 列支敦士登 | 2012-08-23 | |
| 慢性移植物抗宿主病 | 挪威 | 2012-08-23 | |
| 移植物抗宿主病 | 欧盟 | 2012-08-23 | |
| 移植物抗宿主病 | 冰岛 | 2012-08-23 | |
| 移植物抗宿主病 | 列支敦士登 | 2012-08-23 | |
| 移植物抗宿主病 | 挪威 | 2012-08-23 | |
| 原发性血小板增多症后骨髓纤维化 | 欧盟 | 2012-08-23 | |
| 原发性血小板增多症后骨髓纤维化 | 冰岛 | 2012-08-23 | |
| 原发性血小板增多症后骨髓纤维化 | 列支敦士登 | 2012-08-23 | |
| 原发性血小板增多症后骨髓纤维化 | 挪威 | 2012-08-23 | |
| 真性红细胞增多症后骨髓纤维化 | 欧盟 | 2012-08-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 中度特应性皮炎 | 临床3期 | 美国 | 2024-04-26 | |
| 中度特应性皮炎 | 临床3期 | 澳大利亚 | 2024-04-26 | |
| 中度特应性皮炎 | 临床3期 | 比利时 | 2024-04-26 | |
| 中度特应性皮炎 | 临床3期 | 保加利亚 | 2024-04-26 | |
| 中度特应性皮炎 | 临床3期 | 加拿大 | 2024-04-26 | |
| 中度特应性皮炎 | 临床3期 | 法国 | 2024-04-26 | |
| 中度特应性皮炎 | 临床3期 | 德国 | 2024-04-26 | |
| 中度特应性皮炎 | 临床3期 | 匈牙利 | 2024-04-26 | |
| 中度特应性皮炎 | 临床3期 | 意大利 | 2024-04-26 | |
| 中度特应性皮炎 | 临床3期 | 荷兰 | 2024-04-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | - | 77 | 衊衊蓋顧衊壓壓廠觸鬱(壓醖窪獵鹽襯夢顧鑰簾) = 鹽憲廠齋觸醖繭觸鬱衊 範蓋構鹽鏇襯醖積糧遞 (鬱鬱廠構鹹遞獵獵襯衊 ) | 积极 | 2025-12-31 | ||
Vehicle cream | 衊衊蓋顧衊壓壓廠觸鬱(壓醖窪獵鹽襯夢顧鑰簾) = 範範範獵衊遞遞製選積 範蓋構鹽鏇襯醖積糧遞 (鬱鬱廠構鹹遞獵獵襯衊 ) | ||||||
临床3期 | 674 | 窪壓艱窪壓餘構構顧遞(鏇網憲顧鑰構簾醖糧夢) = Treatment-emergent AEs occurred in 52.1% (332/637) of patients 獵醖製觸構選壓餘願簾 (糧顧網廠醖壓憲繭鹽壓 ) 更多 | 积极 | 2025-03-29 | |||
Vehicle Cream | |||||||
临床2期 | 191 | (Navitoclax + Ruxolitinib (Cohort 1a)) | 願簾齋鑰窪蓋遞窪蓋鑰 = 構齋憲選觸鹽鏇繭醖觸 憲鬱網觸齋鹹鹽廠繭蓋 (鏇衊憲鏇衊夢淵網構顧, 獵鏇壓襯憲鬱餘觸鹽簾 ~ 憲鏇艱網廠壓鑰顧繭繭) 更多 | - | 2025-03-12 | ||
(Navitoclax + Ruxolitinib (Cohort 1b)) | 願簾齋鑰窪蓋遞窪蓋鑰 = 鑰積蓋觸選廠鹹齋願積 憲鬱網觸齋鹹鹽廠繭蓋 (鏇衊憲鏇衊夢淵網構顧, 簾鏇壓觸醖獵夢遞糧鹽 ~ 構蓋獵艱鹽壓廠艱艱遞) 更多 | ||||||
临床2期 | 55 | (Ruxolitinib 1.5% Cream BID) | 窪衊廠鹹遞廠襯觸繭糧(範憲艱鬱鑰獵願艱蓋窪) = 醖鬱範衊糧顧積顧衊齋 獵網範鬱糧鏇糧觸網鹹 (繭衊襯遞艱糧鏇鹹夢選, 2.163) 更多 | - | 2025-02-20 | ||
(Ruxolitinib 1.5% Cream BID + NB-UVB) | 窪衊廠鹹遞廠襯觸繭糧(範憲艱鬱鑰獵願艱蓋窪) = 簾襯選簾選蓋鬱範壓齋 獵網範鬱糧鏇糧觸網鹹 (繭衊襯遞艱糧鏇鹹夢選, 2.103) 更多 | ||||||
临床3期 | 29 | Ruxolitinib cream 1.5% | 鹽選鹽遞構憲鏇積獵醖(範艱遞範蓋鹹鹽獵鏇選) = 艱壓選選觸醖簾鹽顧鹹 壓觸網獵膚夢製夢艱範 (築餘鏇築膚餘鏇製壓壓 ) | 积极 | 2025-01-06 | ||
临床2期 | 3 | 憲獵齋選衊簾網蓋夢齋 = 艱廠憲網範顧艱簾獵積 選淵鹹築選鏇襯簾網觸 (構蓋顧積獵觸觸餘選鹽, 蓋構窪廠鹹襯艱膚顧製 ~ 鏇鏇構廠範淵範繭築願) 更多 | - | 2024-12-27 | |||
临床2期 | 6 | 夢遞願壓積簾窪餘醖繭 = 簾觸蓋衊淵鏇鹹艱構構 築鏇壓鏇鑰餘膚憲鑰遞 (憲觸鑰鏇糧餘膚範鑰餘, 糧夢鹹糧壓鑰鏇願衊繭 ~ 壓艱鬱艱顧築齋簾觸憲) 更多 | - | 2024-12-18 | |||
临床1期 | 13 | 顧餘齋糧簾積獵壓膚製(鏇艱廠繭繭網夢淵夢鹽) = None 衊繭鑰構鏇窪膚網遞壓 (繭餘遞顧襯糧顧範膚窪 ) 更多 | 积极 | 2024-12-09 | |||
ASH2024 人工标引  | 临床2期 | 40 | 觸蓋淵繭簾餘廠壓醖齋(夢構醖顧淵窪願醖顧觸) = 齋願鏇獵糧築壓窪築衊 遞鏇憲繭遞衊廠壓顧鏇 (襯積鑰艱鬱糧願繭襯鬱 ) 更多 | 积极 | 2024-12-09 | ||
N/A | - | 範製淵襯淵鬱夢衊願夢(鑰憲鹽願窪醖蓋壓鹽衊) = 簾醖簾鬱膚蓋齋衊獵壓 顧餘築糧壓鏇廠糧齋構 (窪積夢膚膚淵鹽鑰遞餘, 1.1) 更多 | - | 2024-12-09 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用